Urtoxazumab

Urtoxazumab (TMA-15) is a humanized monoclonal antibody against Shiga toxin (Stx) 2[1].

Research Areas >> Infection

Signaling Pathways >> Others >> Others

Urtoxazumab (TMA-15) (0.25-2.5 mg/kg;注射。一次)以时间和剂量依赖的方式改善 B2F1 感染小鼠的致死率[1]。 Animal Model: 5-week-old male DBA/2J mice, STEC B2F1-infection model[1] Dosage: 0.25, 0.5, 1.0, 2.0 and 2.5 mg/kg Administration: Intravenous administration, 1 h before and 12, 24, and 48 h after infection Result: Pretreatment completely protected the infected mice from death, the efficacy of the low dose (0.25 mg/kg) was partial when administered at 12 and 24 h after infection, but the efficacy of the high dose (2.5 mg/kg) was still complete. Prevented death from B2F1 infection in all 20 animals at 1.0 and 2.0 mg/kg 24 h after infection.

[1]. Yamagami S, et al. Efficacy of postinfection treatment with anti-Shiga toxin (Stx) 2 humanized monoclonal antibody TMA-15 in mice lethally challenged with Stx-producing Escherichia coli. J Infect Dis. 2001 Sep 15;184(6):738-42.